University of Iowa Hospitals and Clinics

Clinical Research Studies

Eligibility

Gender



Age Group



More options for age range

Dates

Clinical Research started within last

Names

Principal Investigator

Showing 1 - 4 of 4 results

TIVA

Principal Investigator
Gary L. Pierce, PhD
Department
Department of Health and Human Physiology

Research Study to Investigate the Effects of a Common Anti-inflammatory Drug on Blood Vessel and Heart Function

Healthy, non-smoking adults age 50-79 years are invited to participate in a research study to test the effects of the drug salsalate (similar to aspirin) to test blood vessel and heart function.  Your involvement will include; blood draws, 24 hour blood pressure monitoring, surveys, and tests of blood vessel function.  Compensation will be provided.  For details, please contact Veronica Howsare (319) 467-5677 or email veronica-howsare@uiowa.edu.

 The lead investigator at the University of Iowa is Gary L. Pierce, PhD, Assistant Professor, Health Human Physiology.

age group:50 to 79 years trial start date:August 8, 2012
Gender Preference:none Trial End Date: February 20, 2015
Contact Info:

Veronica Howsare: (319) 467-5677

veronica-howsare@uiowa.edu

Keywords: Anti-Inflammatory Drug ; Blood Vessel Function ; Heart Function

TAH-t Post Markey Surveillance Study

Principal Investigator
Jennifer Goerbig-Campbell, MD
Department
Department or Field of Study

The purpose of this study is to demonstrate that the results achieved in the original pivotal clinical investigation of 81 subjects from five clinical sites are generalizable to new clinical sites that complete the staff training defined in the SynCardia Systems, Inc. Training Manual and who enroll subjects who meet the intended use defined in the product Instructions for Use.

 

Please refer to www.clinicaltrials.gov identifier NCT00614510 for more information.

age group:18 to 99 years trial start date:August 1, 2006
Gender Preference:none Trial End Date: January 31, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email: page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart failure ; Mechanical circulatory support

Freedom Driver Study

Principal Investigator
Jennifer Goerbig-Campbell, MD
Department
Department or Field of Study

The purposes of this study are to confirm that the Freedom Driver System is a suitable pneumatic driver for clinically stable TAH-t subjects, and that patients and lay caregivers can be trained to manage the Freedom Driver System safely outside the hospital.

 

Please refer to www.clinicaltrials.gov identifier NCT00733447 for more information.

age group:18 to 99 years trial start date:March 1, 2010
Gender Preference:none Trial End Date: November 28, 2015
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax: 319-356-7087

email:  page-scovel@uiowa.edu

Keywords: Artificial heart ; cardiac disease ; Cardiomyopathy ; CHF ; Congestive heart failure ; Heart ; heart disease ; Heart Failure ; Mechanical Circulatory Support

Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS)

Principal Investigator
Jennifer Goerbig-Campbell, MD

Over the last two decades, MCSDs have been developed to augment or supplant failing myocardial performance. This therapy has been used successfully as a bridge to heart transplantation, occasionally as a bridge to recovery, and most recently as permanent implantation or "destination therapy" for intractable heart failure. Although heart transplantation offers life-saving therapy for selected patients, its use is limited by a supply of donor organs that currently meets less than one-tenth the need. As a consequence, the number of MCSD implantations has increased in recent years, and this trend is expected to continue especially in light of the October 1, 2003 decision of the Centers for Medicare and Medicaid Services (CMS) to provide reimbursement for MCSD implantation surgery.

Despite favorable survival and quality of life outcomes, MCSDs do have severe and sometimes life-threatening complications, including infection, thrombosis, and device failure. The development of new procedures and devices to reduce these complications will be expedited by the work of the registry involving the systematic, independent analysis of MCSD implantation procedures and outcomes. The National Heart, Lung, and Blood Institute (NHLBI) will collaborate with the CMS and the Food and Drug Administration in monitoring the work of the registry to permit the development of standard reporting of patient characteristics, indications, implantation procedures, and adverse events.

The goals of the registry include the following:

  1. Develop standard methods to collect data and specimens used to characterize heart failure patients receiving MCSDs, and develop methods of collecting demographic data of device use patient outcomes
  2. Collect, process, and store patients' clinical
    age group:0 to 99 years trial start date:February 16, 2007
    Gender Preference:none Trial End Date: November 1, 2015
    Contact Info:

    Jennifer Franzwa, RN at jennifer-franzwa@uiowa.edu

    Julie Shepherd, RN at julie-shepherd@uiowa.edu

    Keywords: Cardiomyopathy ; Cardiovascular Diseases ; CMTP ; Heart ; Heart Diseases ; Heart Failure ; Mechanical Circulatory Support ; Ventricular Assist Device (VAD)
Results per page

Clinical Research Studies

Filters

Your Selections

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.